Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 50 yr, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30-150 mCi are administered for RAI remnant ablation, whereas activities ranging from 150-250 mCi are usually reserved for treatment of metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance for that individual patient.
|Original language||English (US)|
|Title of host publication||Thyroid Cancer (Second Edition)|
|Subtitle of host publication||A Comprehensive Guide to Clinical Management|
|Number of pages||5|
|State||Published - Dec 1 2006|
ASJC Scopus subject areas